Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean calcium magnesium potassium carbonate chloride hydroxide and dopamine?
Displaying drugs 951 - 975 of 14763 in total

Thyroid, porcine

Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is...
Approved
Matched Description: … Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine …

Riluzole

A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Approved
Investigational
Matched Description: … A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong …

Doripenem

Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that...
Approved
Investigational
Matched Description: … to reiterate its safety and efficacy for its approved indications. ... Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal ... In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin …

Atomoxetine

Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention...
Approved
Matched Description: … considered the most effective and first-line treatment for ADHD in adults and children as recommended ... addictive properties, and even amplifies the potency and reinforcing effects of other drugs of abuse ... amphetamines, have a high potential for abuse and dependence. …
Matched Categories: … Psychostimulants, Agents Used for ADHD and Nootropics …

Erlotinib

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... , which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Metixene

Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Approved

Miglitol

Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start...
Approved
Matched Description: … amount of poly and oligosaccharides in the diet. ... Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the ... glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and …
Matched Categories: … Alimentary Tract and Metabolism …

Troglitazone

Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … It was superseded by [pioglitazone] and [rosiglitazone]. …
Matched Categories: … Alimentary Tract and Metabolism …

Reslizumab

Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and promote programmed cell death [A31578]. ... , activation, and survival of eosinophils [FDA Label]. ... for recurrent exacerbation and asthma-related hospitalizations [A31579]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Faricimab

Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and ... retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization ... many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely target VEGF-A. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and ... [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and …

Dabrafenib

Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Barium sulfate

Barium sulfate is an inorganic compound with the chemical formula BaSO4 . Barium sulfate occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield . This drug is used as a contrast agent in...
Approved
Matched Description: … It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation ... Barium sulfate is ingested by mouth or administered rectally and combined with granules of effervescent ... Therapeutic advantages of barium sulfate in diagnostic procedures include both its low water solubility and …

Niraparib

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …

Mexiletine

Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Approved
Investigational

Pefloxacin

A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Approved
Matched Description: … A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …

Paroxetine

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Description: … of serotonin reuptake and has little effect on other neurotransmitters. ... [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. ... uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and …

Flutemetamol (18F)

Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Approved
Investigational
Matched Categories: … Indicators and Reagents …

Imatinib

Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ... [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …

Cobimetinib

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Nomifensine

Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … Also withdrawn from the Canadian and UK markets. …

Mitapivat

Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red...
Approved
Investigational
Matched Description: … alpha- and beta-thalassemia. ... other hereditary red blood cell disorders associated with hemolytic anemia, such as sickle cell disease and …
Matched Categories: … Blood and Blood Forming Organs ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Cocaine

An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of...
Approved
Illicit
Matched Description: … the eye, ear, nose, and throat. ... It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in ... It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse …
Matched Categories: … Analgesics and Anesthetics …

Remestemcel-L

Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … cytokines and growth factors to promote tissue repair [A31818]. ... The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen ... (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells …

Golodirsen

Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD). This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. Often, patients succumb to this condition by age 30 or...
Approved
Matched Description: … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on ... Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Displaying drugs 951 - 975 of 14763 in total